Gasic S, Dudczak R, Korn A, Kletter K
Wien Klin Wochenschr. 1980 Apr 11;92(8):284-90.
The effect of dimeditiapramine (Ro 11-1781), a new calciumantagonist, on thallium-201 myocardial perfusion during exercise was studied in a double-blind trial with 10 patients suffering from coronary heart disease. Treatment with a single intravenous dose of 1 mg/kg body weight resulted in a significant regional thallium-201 perfusion increase in 8 out of 10 patients. These results correspond with the clinically observed decrease in exercise-induced angina and ischaemic ECG alterations. The findings indicate that dimeditiapramine might be a useful anti-anginal drug.
在一项针对10名冠心病患者的双盲试验中，研究了新型钙拮抗剂二甲替嗪（Ro 11 - 1781）对运动期间铊-201心肌灌注的影响。静脉注射单剂量1毫克/千克体重进行治疗后，10名患者中有8名患者的局部铊-201灌注显著增加。这些结果与临床上观察到的运动诱发心绞痛和缺血性心电图改变的减少相一致。研究结果表明，二甲替嗪可能是一种有用的抗心绞痛药物。
